Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Completed Initiated Nov 20, 2023 (3 years ago)

Votrient (pazopanib) (Pazopanib Hydrochloride)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Votrient (pazopanib) 200 mg tablets, 120-count bottle, Rx Only, Manufactured by: Siegried Barbera, S.L., Barbera del Valles, Spain, Distributed by: Novartis Pharmaceuticals Corp., East Hanover, N.J. 07936, NDC 0078-1077-66

Affected NDC 0078-1077-66

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Votrient
pazopanib hydrochloride
NDC 00078-1077
200 mg/1 Tablet, Film Coated
Oral
Novartis Pharmaceuticals Corporation Rx
Recalling firm
Siegfried Barbera, SL
NDC code
0078-1077-66
Origin
N/A, Spain
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0149-2024 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other dissolution failure recalls from 2023

All dissolution failure recalls